THE USE OF RITUXIMAB TO TREAT IGG4 RELATED DISEASE INDUCED CARDIOMYOPATHY
| Autor: | Linnea Lebaron, Jennifer Nickol, Alison Spangler, Dakshin Gangadharamurthy, Dantwan Smith, Wittmann Murphy, Frank McGrew, Thomas Flautt, Christopher L. Smith, Theodore Richards, Likhitesh Jaikumar, John Prather |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
CD20
biology medicine.drug_class business.industry B-cell receptor Cardiomyopathy medicine.disease Monoclonal antibody immune system diseases Apoptosis hemic and lymphatic diseases medicine Cancer research biology.protein IgG4-related disease Rituximab Antibody Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 75:3373 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(20)34000-6 |
| Popis: | Rituximab is a chimeric monoclonal antibody against the protein CD20 which is predominantly found on the surface of B cells. Malignant B cells express higher levels of CD20. Rituximab not only induces cellular apoptosis but also down regulates the B cell receptor and mediates antibody dependent |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|